EP3551538A1 - Device for preparing radioactive solutions - Google Patents
Device for preparing radioactive solutionsInfo
- Publication number
- EP3551538A1 EP3551538A1 EP17811538.2A EP17811538A EP3551538A1 EP 3551538 A1 EP3551538 A1 EP 3551538A1 EP 17811538 A EP17811538 A EP 17811538A EP 3551538 A1 EP3551538 A1 EP 3551538A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- support block
- syringe
- cells
- opening
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002285 radioactive effect Effects 0.000 title claims abstract description 16
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 9
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 8
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 6
- 230000003471 anti-radiation Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical group [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000004891 communication Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F7/00—Shielded cells or rooms
- G21F7/005—Shielded passages through walls; Locks; Transferring devices between rooms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
- B65B3/006—Related operations, e.g. scoring ampoules
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F5/00—Transportable or portable shielded containers
- G21F5/015—Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation units; Radioisotope containers
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/0005—Isotope delivery systems
Definitions
- the field of the invention is that of the preparation of radioactive solutions, and in particular of radiopharmaceutical drugs.
- the invention relates more particularly to a device for preparing such radioactive solutions and radiopharmaceutical drugs.
- radiopharmaceutical drugs contain artificial radioelements called radionuclides, which are used for diagnostic or therapeutic purposes and used in nuclear medicine departments.
- These medicinal products are either in the form of proprietary medicinal products containing radionuclides which are delivered ready for use, or in the form of radiopharmaceutical preparations which are prepared in situ and extemporaneously by labeling of carrier molecules, referred to as "kits” by the skilled person, with a chosen radionuclide from a generator.
- kits carrier molecules
- the most commonly used radionuclide in nuclear medicine is technetium 99m ( 99m Tc), which is readily available from the 99mMb / 99mTc generator and is administered as a sodium pertechnetate solution.
- kits are sterile and pyrogen-free substances, which are pre-packaged most often in the form of vials closed vacuum sealed.
- it is generally used for the preparation of these drugs shielded enclosures (against isotope radiation) provided with round-type openings of gloves on the edges of which are fixed latex gloves where the operators introduce the hands.
- Some centers use enclosures that do not have integral gloves, replaced by traditional disposable latex or nitrile gloves worn by the user and changed with each manipulation.
- the preparations are made by transfer of a diluted eluate to the kit vial using disposable syringes. Once the RPM solution has been prepared, and passed through the activimeter, a sealed syringe protector is installed on the syringe.
- the object of the invention is to provide a device for the preparation of radiopharmaceuticals which allows an automated preparation of radioactive solutions and minimizes the exposure of operators to radiations emitted by radionuclides.
- the present invention proposes a device for preparing radioactive solutions comprising: a mobile support block comprising at least two cells capable of receiving a bottle; an armored (anti-radiation) screed, comprising a side wall surrounding the periphery of the support block and an upper wall covering the upper face of the support block, an opening being provided in the upper wall of the screed; a carrier block drive means configured to selectively move the block into positions, said working positions, in which a given cell is aligned with the opening to allow access to said cell from the outside of the yoke; a syringe holder associated with a syringe actuating means configured to move a syringe vertically substantially in the axis of the opening and to actuate a piston of said syringe.
- the support block is configured so that it can be further brought into a position, called the closed position, in which the opening is closed by a shielded element carried by the support block.
- the device equipped with several cells, makes it possible to carry out the preparations required for the use of RPM, whether reconstructions, markings and splits, or simple dilutions and transfers between flasks.
- the use of the device is not limited to the preparation of RPM, but can be used for the preparation of any radioactive solution.
- the shielded element carried by the support block can be integral with it, for example if the support block is also made of material for blocking or attenuating the isotope radiation, or reported therein.
- the shielded element may for example be a disc made of lead-based material (or other suitable anti-radiation material) placed in a housing opening into an upper face of the movable support block.
- the armored screed is made of any material used to attenuate or block the passage of radiation emitted by the isotopes placed in the screed, for example lead, lead-based material, or other antiradiation materials. The thickness of the armored screed is adjusted according to the doses contained and the desired attenuation.
- the mobile support block is a cylindrical barrel rotatably mounted, preferably about a central axis substantially vertical, and in which the cells open into the upper face of the barrel.
- the cells and the housing of the shielded element are positioned in the barrel so as to bring them selectively, by rotation of the barrel, in alignment with the opening of the yoke.
- the device has one or more of the following technical characteristics:
- the cells capable of accommodating flasks are cylindrical cells inclined with respect to the vertical;
- one or more cells comprise a temperature sensor and / or a precision balance at the bottom of the cell;
- optical detection means for detecting the angular position of the mobile support block, preferably optical detection means
- heating and / or cooling means are associated with at least one of the cells
- a cell is formed as an insert mounted in a hollow portion of the support block, the heating and / or cooling means comprising a heating resistor mounted on a sleeve disposed in a cell, and a fan mounted in the block support and ventilation openings in the side wall of the support block.
- a disinfection means equips at least one, preferably each of the cells. It comprises, for example, a circular ramp of UV emitters at around 254 nm, positioned on the upper circumference of the cell and preferably oriented towards the inside of the cell, towards the bottle.
- the syringe actuating means comprises a first mobile whose syringe door is secured, the syringe holder ensuring the maintenance of the syringe body and a second mobile with means for coupling to the syringe piston.
- the syringe actuating means is configured to either simultaneously move the first and second mobile, or to perform the movement of the second mobile relative to the first mobile.
- the device also advantageously comprises translational means mounted on the first mobile, in order to move the syringe holder laterally relative to the support block; and / or the syringe holder is associated with a support and comprises means for moving the syringe holder downwards relative to its support.
- Fig.1 a perspective view of an embodiment of a device for preparing radiopharmaceutical injections according to the invention
- Fig.2 a perspective view of the device of Fig. 1, without the shielded housing;
- Figs.3 a perspective view of the barrel
- Fig.4 a vertical sectional view through the central axis of the barrel
- Fig.5 a sectional view of the device of Fig. 1, with the barrel in the working position
- Fig.6 a sectional view of the device of Fig. 1, with the barrel in the closed position;
- Fig.7 a front view of Fig.2
- Fig.8 a perspective view of the syringe housing, hood open;
- Fig.9 a perspective view of the syringe housing, lowered on its support.
- the present invention relates to a device for preparing radioactive solutions and in particular radiopharmaceutical preparations allowing the collection of products in bottles in an automated manner, and guaranteeing the safety of the user.
- the device is in particular designed to allow the preparation of RPMs, in particular RPM injections, combining a radioisotope with a vector, that is to say a molecule (or fragment) chosen to selectively locate on a particular structure of the body.
- the device for preparing RPM injections 10 which comprises a movable support block 12 comprising a plurality of cells 14 adapted to receive a bottle.
- the support block 12 is intended to accommodate different bottles for the reconstitution of RPM or fractionation, for the preparation of injections.
- the vials used are vials in penicillin bottle format (example: diameter 2.5 cm, height 5.5 cm) with a rubber cover on the top opening and called “kits”.
- Other bottles can of course be used, and the dimensions of cells 14 adapted accordingly.
- the device advantageously comprises a shielded casing around the support block.
- the protective case is a "shielded" screed 16, which comprises a side wall 18 surrounding the periphery of the support block 12 and an upper wall 20 covering the upper face 22 of the support block 12.
- An opening 24 is provided in the upper wall 20 of the housing, to allow access to the cells 14.
- the armored cap 16 may be made of lead, for example with a thickness of the order of for example 9 to 30 mm or any other material to make screen (attenuate or block) to radionuclide emissions.
- the wall thickness is chosen to attenuate the ionizing radiation according to the material used and the dose of isotopes.
- the reference numeral 26 generally designates a syringe actuating means configured to move a syringe vertically, substantially in the axis of the opening, and to actuate a plunger of said syringe, as described in more detail hereinafter .
- the reference sign 27 designates a syringe holder for a syringe 29 (visible in FIG. 5).
- the support block 12 is preferably made as a rotary barrel, a term that will be adopted for the following description.
- the device 10 comprises a driving means of the barrel 12 which is configured to selectively move the barrel 12 in positions, called working positions, in which a given cell 14 is aligned with the opening 24 to allow access to the barrel 12. from the outside of the housing 16.
- the barrel 12 comprises a generally cylindrical body, with a cylindrical side face 28 of axis A, the upper face 22 and a lower face 30. In the device, the barrel 12 is arranged with its lower face 30 facing downwards. .
- the barrel 12 is rotatably mounted on a plate 32 which forms the base of the device 10 and also supports the armored cap 16 (the plate 32 may be of anti-radiation material, but this is often not necessary because the device is placed on shielded support).
- the plate 32 may be of anti-radiation material, but this is often not necessary because the device is placed on shielded support.
- it comprises a central cylindrical housing 34 opening into the lower face 20, as shown in Fig.4.
- An axis 36 extends perpendicularly to the plate 32 and engages in the housing 34.
- the axis 36 has a diameter corresponding substantially to the inside diameter of the housing 34, to the operating clearance, so as to allow the rotation of the barrel around the axis 36 (coincides with the axis A).
- a ring 38 possibly toothed, surrounding the axis 36.
- the ring gear 38 allows a rotation drive, for example by belt (not shown), the barrel 12 on the axis 34.
- This belt is also engaged on a drive pulley (not shown) integral with an output shaft of a motor assembly 40 of a cylinder, mounted on the plate 32.
- the cylinder 12 comprises four cells 14 (also individually designated 14.1 to 14.4) adapted to receive vials for the preparation of solutions.
- the cells 14 are designed to open into the upper face 22 of the cylinder 12.
- the cells 14 are preferably of cylindrical shape (circular section or other), but advantageously have their axis (B) inclined relative to the vertical, for example of 15 to 20 °. This facilitates the removal in the bottom of the bottle when the remaining volume is low.
- the diameter of the barrel 12, and the dimensions of the cells depend on the flasks to be accommodated and therefore the intended applications.
- the cells 14 may have a depth between 35 and 70 mm.
- the inlet diameter of the cells 14 is adapted to the flasks and the passage section of the opening 24 is preferably slightly smaller than the inlet diameter of the cells 14.
- the barrel 12 comprises in fact a fifth cell 15, called housing, designed to accommodate lead (the cell is empty in Fig.3).
- a lead element 17 for example a disk or cylinder of shape complementary to the housing (FIG. 2).
- the drive means constituted by the motor assembly 40 connected to the ring gear 38 makes it possible to pivot the barrel 12 so as to be able to selectively align each of the cells 14.1 to 14.4 with the opening 22, thus allowing the access to the flasks contained in these cells from the outside of the housing, forming the working positions.
- the driving means also makes it possible to put the barrel 12 in the closed position, in which the housing 15 is aligned with the opening 24 and the lead element 17 closes the opening 24.
- the barrel 12 can be made of any material and by any suitable method. In particular, it can advantageously be produced in a rigid polymer, such as ABS. 3D printing is an advantageous manufacturing technique, but other techniques can be used.
- the four cells 14.1 to 14.4 intended to accommodate vials and the cell 15 accommodating the lead disc 17 have the center of their upper openings, in the plane of the upper face 22 of the barrel, equidistant from the axis of rotation A. Of course, this distance is substantially the same as the distance from the axis A to the center of the opening 24. This allows to align any of the cells 14.1 to 14.4 and 15 with the opening 24, by rotating the barrel around of its axis.
- the cell 14.4 comprises a tubular liner closed at its lower end, which is placed in a hollow region of the barrel 12.
- the liner 42 comprises an upper rim 44 by which it bears on the upper face 22 of the barrel. barrel.
- Heating and / or cooling means can therefore be provided for one or more cells.
- a heating resistive wire 42.1 is preferably wound around the jacket 42. Forced cooling of this jacket 42 is obtained by means of a fan (not shown) placed in the hollow region of the barrel 12, which has an opening 46 in the lateral face 28, under the cell 15.
- a series of lamellar openings 48 are also made in the side wall 28 of the cylinder 12.
- each cell 14 with a flask is equipped with a temperature sensor 19 (FIG. 4).
- the cell 14.4 may comprise 2 temperature sensors.
- a precision balance 21 (FIG. 4) is advantageously provided at the bottom of each cell 14.1 to 14.4. The scales allow to know in real time the volume present in each bottle.
- Angular position detection (hourly) means of the barrel are advantageously provided for an increased precision of the positioning of the barrel 12 relative to the orifice 24.
- Optical means (not shown) are preferred.
- the barrel is equipped with a barcode determining the position of each cell 14.1 to 14.4 and 15.
- a barcode reader placed is placed in the yoke 16.
- This disinfection means may comprise a ramp of UV emitting lamps around 254 nm (for example LEDs), positioned on the upper circumference (entry) of the cell and oriented towards the inside of the cell, towards the upper face of the bottle.
- the ramp of LEDs is indicated 23 in FIG.
- the syringe actuating means 26 which is mounted on the plate 32 at the rear of the cylinder 12. It comprises two movable elements 52 and 54 (called simply 'mobile') sliding vertically along two fixed axes 56 and 58, smooth and vertical; and driven along these axes 56, 58 by means of two worms 60 and 62 formed by threaded rods.
- Each of the mobiles 52, 54 comprises a horizontal support plate 52.1, 54.1 with two orifices traversed by the sliding pins 56, 58.
- Each support plate 52.1, 54.1 carries, at the sliding orifices, a guide sleeve 64 aligned with this last, to improve the horizontal stability when moving along the axes 56, 58.
- the lower support plate 52.1 comprises an orifice through which the worm 60 passes and a screw thread formed by a threaded sleeve 66, fixed on the support plate 52.1 and aligned with said orifice.
- the thread of the sleeve 66 corresponds to that of the worm 60 and thus allows the ascending or lowering of the support plate 52.1 along the worm 60, in the direction of rotation of the screw 60.
- screw 60 is rotated by a first motor assembly 67 resting on the plate 32.
- the upper support plate 54.1 comprises a passage opening (smooth) for the worm 60 which drives the lower support plate 52.1.
- the thread of the sleeve 68 corresponds to that of the worm 62 and allows the ascent or descent of the plate 54.1 along the screw 62, according to the direction of rotation thereof.
- the screw 62 is rotated by a second motor assembly 70 attached to the lower support plate 52.1.
- the second motor assembly 70 is preferably fixed under the lower support plate 52.1 and the connection with the worm 62 is through an orifice formed in the plate 52.1.
- actuation of the first motor assembly 67 alone allows simultaneous movement of the support plates 52.1 and 54.1, which is useful for moving the entire syringe relative to the barrel.
- the actuation of the second motor assembly 70 causes a relative displacement between the two support plates 52.1 and 54.1, which thus makes it possible to move the piston of the syringe relative to the syringe body.
- a position sensor for example of the potentiometer type, is advantageously associated with each mobile 52 and 54 to determine their respective vertical position with good accuracy. Knowing the relative displacement between the two mobiles 52, 54 makes it possible to know the stroke of the piston and thus to calculate the volumes introduced into the syringe body or expelled.
- each support plate comprises on their inner faces vertical guide means for the mobile, here in the form of a vertical rib 74 of triangular profile, placed in the center of the amount.
- Each support plate comprises at its longitudinal ends a triangular incision 76 of shape corresponding to the ribs 74, to improve the stability of the guide.
- Each of the two mobiles 52, 54 comprises gripping means for the syringe.
- Reference sign 80 designates a form actuating arm triangular, integral with the upper support plate 54.1, projecting from the side of the barrel 12.
- the arm 80 is slidably mounted on a pair of rails 81 attached to the second plate 54.1, in order to move toward or away from the syringe plunger head to engage it. This movement is controlled by a motor assembly 83 driving a worm.
- the syringe body is received and blocked in the syringe holder 27 associated with the support plate 52.1.
- the syringe holder 27 comprises, in the manner of a box, a base 86 and a cap 88 pivoting relative to this base by means of a lateral hinge 90 (FIGS. 8 and 9).
- a latch (not shown remotely) is provided to hold the cover 88 in the closed position on the base 86.
- the inner portions facing the base 86 and the cover 88 each include a footprint so as to define a housing for the seat.
- FIG. 8 shows the cavities 92, 92 'for the cylindrical syringe body, and horizontal slots 93, 93' for receiving the end flange of the syringe body.
- the syringe body 90 is firmly held in the syringe holder 27 integral with the lower support plate 52.1 and the syringe piston 92, the end of which is engaged in the actuating arm 80 secured to the upper support plate 54.1, can be manipulated individually by actuation of the second motor assembly 70.
- the syringe holder 27 is mounted on a support 94, which slides on two horizontal smooth rods 96, transversely to the vertical axis of movement of the syringe holder 27 by means of the mobiles 52 and 54.
- the support 94 which has for example a square plate shape, comprises on the rear face two cylindrical bearings 98 in which the rods 96 are engaged. As can be seen in the figures, the rods 96 are fixedly held parallel at their ends by two arms 100 integral with the plate. lower support 52.1.
- a drive means is provided for moving the holder 94 of the syringe holder along the rods 96, for selectively positioning the syringe holder 27 on either side of the barrel 12 to bring the syringe to a device or accessory placed just in front of the barrel. 12.
- the reference sign 101 designates a motor assembly fixed on the outer side of an arm 100.
- the drive of the holder 94 of the syringe holder is moved on the rods 96 by means of a belt (not shown) which is driven by the motor 101 and supported by a pulley (not shown) attached to the arm 100 opposite the motor 101.
- the syringe holder 27 is advantageously mounted to move relative to its support 94, in order to lower the syringe holder 27 relative to the vertical position of the lower support plate 52.1.
- the syringe holder 27 is lowered relative to its holder 94.
- the syringe holder 27 is connected to the support 94 by means of two drive links (not shown) which are actuated by an assembly. 102.
- Two centering cones 104 are arranged vertically and fixed to lugs 106 integral with the upper edge of the support 94.
- the centering cones 104 cooperate with conical housings 108 in the upper face of the base 86 of the syringe holder 27.
- the drive links are guided vertically through a central passage in the centering cones 104 and also through the conical housings 108.
- FIG. 5 respectively illustrate a working position and the closed position of the barrel.
- the barrel 12 is positioned with the housing 14.1 aligned with the opening 24.
- the door syringe 27 rests on its support 94 and the mobile 52 is in the low position: the needle 1 10 attached to the end of the syringe 29 is in the cell 14.1 and is engaged in a bottle 1 12.
- the syringe plunger 92 can be maneuvered with the help of the mobile 54 to withdraw liquid from the flask, or inject a quantity from the syringe into the flask 1 12.
- sampling or injection operations can be performed for a bottle housed in any of the cells 14.1 to 14.4, aligning the cell with the opening 24, that is to say in the working positions of the barrel 12 .
- the armature sidewall 18 of the armature 16 also includes a rear wall 18.1, thus enclosing the entire periphery of the barrel 12.
- the barrel 12 is in an angular position in which the cell / housing 15 carrying the lead disc 17 is aligned with the opening 24: it is the closed position of the barrel 12.
- the syringe holder 27 is of course raised, to disengage the syringe 29, respectively the needle, from the orifice 24.
- the lead disc 17 closes the opening 24, physically blocking the communication with the the interior of the yoke 16, and also blocking the isotope emissions through the opening 24.
- An operator can then manipulate the syringe holder 27, especially for the introduction of a new syringe, without fear of taking a flow of radioactive doses at the end of his fingers.
- the device preferably comprises a control module managed by software, preferably external to the device, for controlling: the rotational movements of the barrel, the movements of the mobiles 52 and 54 and thus keep a history ( log) withdrawn quantities, and movements of the syringe holder 27.
- a control module managed by software, preferably external to the device, for controlling: the rotational movements of the barrel, the movements of the mobiles 52 and 54 and thus keep a history ( log) withdrawn quantities, and movements of the syringe holder 27.
- the device 10 will, in use, typically be placed in a shielded glove box.
- the first bottle contains the metastable Technetium 99 (Te 99m * ) isotope initially diluted in 5ml of aqueous sodium chloride (NaCl). We do not speak of concentration for the measurement in this case, but of radioactive activity which depends on the elution age of the technetium (taken from the mother fountain present in the preparation chamber).
- marking that is to say the preparation of a pot for a specific marker (example: bone pot);
- Each type of scintigraphic examination requires its specific marker that will vector technetium to the region to be explored and thus its own pot.
- the device ensures the preparation of two types of markers as soon as it is necessary, and a first time at the beginning of the session.
- the second vial contains the necessary NaCl to make dilutions.
- the third vial will become the bone marker for bone scintigraphy.
- a vial as packaged filled with HDP Hydrogen
- HDP Hydrogen
- Osteocis Hydrogen
- the device 10 is responsible for filling this third bottle with the solution Te + NaCl.
- the barrel 12 is then rotated to facilitate the dilution of the powder in the Te + NaCl.
- the ideal volume activity is 750Mbq / mL.
- the fourth vial will become the cardiac marker for cardiac scintigraphy.
- the bottle is initially loaded into the cell, in particular cell 14.4, as it is sold filled with mibi (sestamiBi) in the form of a powder.
- the device is responsible for filling this fourth bottle with the solution of Te + NaCl.
- the barrel 12 is then rotated to facilitate the dilution of the powder in the Te + NaCl.
- the heating function of cell 14.4 is also activated.
- the ideal volume activity is 260Mbq / mL.
- the prescriptions of the vector manufacturers will generally be followed.
- the scales enable the device in real time to know the volume present in each bottle, the heating device only concerns the cardiac marker (mibi). Before a marking, the device will go and take NaCI in the dedicated bottle to dilute the source pot, then take from this source pot, the activity necessary to inject to perform a reconstitution (marking) of a kit according to the activity of the day or request of the user.
- the cardiac marker mibi
- the device will go and take NaCI in the dedicated bottle to dilute the source pot, then take from this source pot, the activity necessary to inject to perform a reconstitution (marking) of a kit according to the activity of the day or request of the user.
- Fractionation the dose to be prepared for the patient is unique and depends on the weight of the patient. It is read by the operator from a weight-dose chart.
- the operator draws from a syringe, and in his experience, a volume of radioactive drug in a source pot corresponding at first sight to the need for product according to the weight of the patient and then measures the dose contained in the syringe in a counting well that will measure the radioactivity. If the "amount" of radioactivity does not correspond to what is necessary for the patient, it is necessary, in conventional preparation methods, to manually adjust the dose present in the syringe to or from the source pot and repeat the procedure. measured as many times as necessary to arrive at a measurement corresponding to the amount of radioactivity required by the patient. It will be appreciated that the fractionation is largely facilitated by the present device 10.
- the device 10 does not need to effector the "round trips" described above, and takes from the outset, in the requested kit, the volume corresponding to the activity requested. Then, the syringe is measured in a counting well contained in the preparation chamber by the lateral translation on the rods 96, before being deposited in a tungsten protective case, when the preparation is finished.
- the invention is not limited to the embodiment which has just been described by way of example, but covers all variants thereof.
- the barrel 12 is a particular embodiment of a movable support block, but could take other forms to perform the bottle receptacle function with its cells / well.
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- High Energy & Nuclear Physics (AREA)
- Mechanical Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1662069A FR3059567B1 (en) | 2016-12-07 | 2016-12-07 | DEVICE FOR PREPARING RADIOACTIVE SOLUTIONS |
PCT/EP2017/081532 WO2018104306A1 (en) | 2016-12-07 | 2017-12-05 | Device for preparing radioactive solutions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3551538A1 true EP3551538A1 (en) | 2019-10-16 |
EP3551538B1 EP3551538B1 (en) | 2021-02-03 |
Family
ID=58645141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17811538.2A Active EP3551538B1 (en) | 2016-12-07 | 2017-12-05 | Device for preparing radioactive solutions |
Country Status (6)
Country | Link |
---|---|
US (1) | US10755828B2 (en) |
EP (1) | EP3551538B1 (en) |
JP (1) | JP2020500642A (en) |
ES (1) | ES2868787T3 (en) |
FR (1) | FR3059567B1 (en) |
WO (1) | WO2018104306A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109896054A (en) * | 2019-03-25 | 2019-06-18 | 常州市第二人民医院 | A kind of micro- radiation subpackage apparatus of radiopharmaceutical |
EP3754383A1 (en) | 2019-06-18 | 2020-12-23 | Université de Lorraine | Device for the preparation of radioactive solutions |
CN115367234B (en) * | 2022-10-10 | 2023-01-31 | 山东省蓬莱制药机械厂有限公司 | Full-automatic powder liquid filling machine with adjustable xiLin bottle specification |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE902407R (en) * | 1984-10-19 | 1985-09-02 | Karlsruhe Wiederaufarbeit | DEVICE FOR TAKING SAMPLES ESPECIALLY FOR TOXIC AND / OR RADIO-ACTIVE SUBSTANCES. |
US7750328B2 (en) * | 2006-10-27 | 2010-07-06 | Draximage General Partnership | Filling system for potentially hazardous materials |
-
2016
- 2016-12-07 FR FR1662069A patent/FR3059567B1/en active Active
-
2017
- 2017-12-05 WO PCT/EP2017/081532 patent/WO2018104306A1/en unknown
- 2017-12-05 EP EP17811538.2A patent/EP3551538B1/en active Active
- 2017-12-05 ES ES17811538T patent/ES2868787T3/en active Active
- 2017-12-05 US US16/466,806 patent/US10755828B2/en active Active
- 2017-12-05 JP JP2019530831A patent/JP2020500642A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3551538B1 (en) | 2021-02-03 |
FR3059567A1 (en) | 2018-06-08 |
JP2020500642A (en) | 2020-01-16 |
WO2018104306A1 (en) | 2018-06-14 |
US10755828B2 (en) | 2020-08-25 |
US20190341162A1 (en) | 2019-11-07 |
ES2868787T3 (en) | 2021-10-21 |
FR3059567B1 (en) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3551538B1 (en) | Device for preparing radioactive solutions | |
EP2179926B1 (en) | Sterile, single-use device for preparing a radiopharmaceutical drug, system and method implementing this device | |
US20100331600A1 (en) | System for dispensing radio-pharmaceuticals and measuring radiation dosage of it | |
US5479969A (en) | Apparatus for dispensing substances which are biologically hazardous | |
CA2624744C (en) | Filling system for potentially hazardous materials | |
EP2077873B1 (en) | Medical unit for the collection, calibration, dilution and/or injection of an injectable radioactive product | |
AU2003209692B2 (en) | Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere | |
KR101283345B1 (en) | Apparatus for dispensing radio-pharmaceuticals and measuring radiation dosage of it | |
CH443498A (en) | Method for quantitatively determining the degree of attenuation of radioactive emissions in n separate samples, and apparatus for carrying out this method | |
WO1994004415A1 (en) | Apparatus for dispensing substances which are biologically hazardous | |
EP2668101B1 (en) | Single-use sterile device for filling syringes with radiopharmaceutical drugs, and automatic system and method for filling syringes using said device | |
FR2739565A1 (en) | Preparing radioactive solution for injection | |
FR2956091A1 (en) | Blister type single use sterile device for injecting radiopharmaceutical medication into syringe, has safety connector that is connected to another safety connector interconnected to patient syringe, where connectors are fixed on cylinder | |
WO2013045421A1 (en) | Device | |
KR101365269B1 (en) | Apparatus for dispensing radio-pharmaceuticals and measuring radiation dosage of it | |
WO2008117097A2 (en) | Filling system for potentially hazardous materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190614 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: THOMAS, QUENTIN Inventor name: MATHIAS-LAOT, GUENOLE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200717 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1359654 Country of ref document: AT Kind code of ref document: T Effective date: 20210215 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017032361 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: OFFICE ERNEST T. FREYLINGER S.A., CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1359654 Country of ref document: AT Kind code of ref document: T Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210503 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210504 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210503 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210604 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210603 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2868787 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211021 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017032361 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20211104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211205 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20171205 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231128 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231127 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231201 Year of fee payment: 7 Ref country code: FR Payment date: 20231127 Year of fee payment: 7 Ref country code: DE Payment date: 20231128 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240118 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240101 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210203 |